Wedekind, Dirk

[["dc.bibliographiccitation.firstpage","133"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","138"],["dc.bibliographiccitation.volume","261"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Neumann, Karolin"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Engel, Kirsten Rita"],["dc.contributor.author","Jamrozinski, Katja"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:58:43Z"],["dc.date.available","2018-11-07T08:58:43Z"],["dc.date.issued","2011"],["dc.description.abstract","Elevations of serum homocysteine levels are a consistent finding in alcohol addiction. Serum S100B levels are altered in different neuropsychiatric disorders but not well investigated in alcohol withdrawal syndromes. Because of the close connection of S100B to ACTH and glutamate secretion that both are involved in neurodegeneration and symptoms of alcoholism the relationship of S100B and homocysteine to acute withdrawal variables has been examined. A total of 22 male and 9 female inpatients (mean age 46.9 +/- A 9.7 years) with an ICD-10 diagnosis of alcohol addiction without relevant affective comorbidity were examined on admission and after 24, 48, and 120 h during withdrawal. S100B and homocysteine levels in serum were collected, and severity of withdrawal symptoms (AWS-scale), applied withdrawal medication, initial serum ethanol levels and duration of addiction were recorded. Serum S100B and homocysteine levels declined significantly (P < .05) over time. Both levels declined with withdrawal syndrome severity. Females showed a trend to a more intense decline in serum S100B levels compared to males at day 5 (P = .06). Homocysteine levels displayed a negative relationship to applied amount of clomethiazole (P < .05) and correlated with age of onset of addiction. No withdrawal seizures were recorded during the trial. As it is known for homocysteine, S100B revealed to decline rapidly over withdrawal treatment in alcoholism. This effect is more pronounced in female patients. S100B could be of relevance in the neurobiology of alcohol withdrawal syndromes. It may be indirectly related to the level of stress level or glutamatergic activity during alcohol withdrawal."],["dc.identifier.doi","10.1007/s00406-010-0121-2"],["dc.identifier.isi","000287859300007"],["dc.identifier.pmid","20593192"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6616"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23711"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0940-1334"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","S100B and homocysteine in the acute alcohol withdrawal syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","441"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Psychiatry"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2022-07-01T07:35:22Z"],["dc.date.available","2022-07-01T07:35:22Z"],["dc.date.issued","2022"],["dc.date.updated","2022-07-25T11:18:54Z"],["dc.description.abstract","Background During the COVID-19 pandemic, internet-delivered psychotherapeutic interventions (IPI) move increasingly into the focus of attention. Method We reviewed 39 randomized controlled studies of IPIs with 97 study arms ( n  = 4122 patients) for anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, and social anxiety disorder) and performed a meta-analysis. Most studies were conducted with cognitive behavioural approaches (iCBT). Results were compared with a previous meta-analysis examining medications and face-to-face (F2F) psychotherapy. Results In direct comparisons, IPIs were as effective as F2F-CBT and superior to waitlist controls. Programs with more intensive therapist contact yielded higher effect sizes (ES). We compared the obtained ES with a previous comprehensive meta-analysis of 234 studies. In this comparison, iCBT was less effective than individual F2F-CBT and medications, not different from pill placebos, and more effective than psychological placebo and waitlist ( p  > .0001 for all comparisons). ES of IPIs may be overestimated. Treatments were only compared to waitlist, which is not a sufficient control condition. 97% of the studies were not blinded with regard to the main outcome measure. 32% of the participants received antianxiety drugs during the trials. In 89%, participants were recruited by advertisements rather than from clinical settings, and 63% of the participants had an academic background (students or university employees) which might affect the generalizability of the findings. Remote diagnoses were often made by students without completed training in psychotherapy. In only 15% of the studies, diagnoses were made in personal contact with a psychiatrist or psychologist. In 44% of the studies, the ‘therapists’ maintaining remote contact with the participants were mostly students without completed psychotherapy education. Conclusions IPIs may be a useful tool when face-to-face psychotherapy is not easily available, or as an add-on to standard psychotherapeutic or psychopharmacological treatments but should perhaps not be used as monotherapy. We have suggested standards for future research and the practical use of IPIs."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.citation","BMC Psychiatry. 2022 Jun 29;22(1):441"],["dc.identifier.doi","10.1186/s12888-022-04002-1"],["dc.identifier.pii","4002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112151"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","1471-244X"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject","Anxiety disorders"],["dc.subject","Panic disorder"],["dc.subject","Generalised anxiety disorder"],["dc.subject","Social anxiety disorder"],["dc.subject","Internet psychotherapy"],["dc.subject","Meta-analysis"],["dc.title","Internet psychotherapeutic interventions for anxiety disorders – a critical evaluation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Psychiatry"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Raue, Stefan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schmidt, Ulrike"],["dc.date.accessioned","2020-12-10T18:46:52Z"],["dc.date.available","2020-12-10T18:46:52Z"],["dc.date.issued","2019"],["dc.description.abstract","The metabolic syndrome (MetS) comprises abdominal obesity, preclinical or full diabetes type 2, arterial hypertension, and dyslipidemia and affects a significant proportion of the general population with a remarkably higher prevalence in patients suffering from psychiatric disorders. However, studies exploring the pathogenetic link between MetS and psychiatric diseases are rare. Here, we aim to narrow this gap in knowledge by providing a narrative review on this topic that focuses on two psychiatric diseases, namely on schizophrenia and posttraumatic stress disorder (PTSD) since we assume them to be associated with two different main causalities of MetS: in schizophrenia, MetS evidently develops or aggravates in response to antipsychotic drug treatment while it assumingly develops in response to stress-induced endocrine and/or epigenetic alterations in PTSD. First, we compared the prevalences of MetS and associated pathologies (which we took from the latest meta-analyses) among different psychiatric disorders and were surprised that the prevalences of arterial hypertension and hyperglycemia in PTSD almost doubles those of the other psychiatric disorders. Next, we performed a literature search on the neurobiology of MetS and found numerous articles describing a role for proopiomelanocortin (POMC) in MetS. Thus, we concentrated further analysis on POMC and one of its downstream effector hormones, α-melanocyte-stimulating hormone (α-MSH). We found some evidence for a role of POMC in both PTSD and schizophrenia, in particular in antipsychotic-induced MetS, as well as for α-MSH in schizophrenia, but, surprisingly, no study on α-MSH in PTSD. Taken together, our synopsis reveals, first, a potential interaction between the POMC system and stress in the assumingly at least partially shared pathogenesis of psychiatric disorders and MetS, second, that modulation of the POMC system, in particular of the melanocortin 3 and 4 receptors, might be a promising target for the treatment of MetS and, third, that the DNA methylation status of POMC might speculatively be a promising biomarker for MetS in general and, possibly, in particular in the context of stress-related psychiatric conditions such as PTSD. To best of our knowledge, this is the first review on the role of the POMC system in MetS in psychiatric disorders."],["dc.identifier.doi","10.3389/fpsyt.2019.00834"],["dc.identifier.eissn","1664-0640"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16693"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78574"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-0640"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Human Psychopharmacology: Clinical and Experimental"],["dc.bibliographiccitation.volume","36"],["dc.contributor.affiliation","Meiser, Miriam; 1\r\nDepartment of Psychiatry and Psychotherapy\r\nUniversity of Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Wiltfang, Jens; 1\r\nDepartment of Psychiatry and Psychotherapy\r\nUniversity of Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Bandelow, Borwin; 1\r\nDepartment of Psychiatry and Psychotherapy\r\nUniversity of Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Wedekind, Dirk; 1\r\nDepartment of Psychiatry and Psychotherapy\r\nUniversity of Göttingen\r\nGöttingen Germany"],["dc.contributor.author","Timäus, Charles"],["dc.contributor.author","Meiser, Miriam"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2021-06-01T09:41:52Z"],["dc.date.available","2021-06-01T09:41:52Z"],["dc.date.issued","2021"],["dc.date.updated","2022-03-21T08:29:55Z"],["dc.description.abstract","Abstract Objective The endogenous opioid system is assumed to be involved in the pathophysiology of borderline personality disorder (BPD), and opioid antagonists may improve core features of BPD. The aim of this retrospective chart analysis was to evaluate the relative contribution of the opioid antagonist naltrexone and other psychotropic drugs in the improvement of overall symptomatology in BPD. Methods One hundred sixty‐one inpatients with BPD treated between January 2010 and October 2013 were classified as either treatment responders or non‐responders. Treatment responders were defined as subjects with significant improvements in four or more symptoms from a defined symptom list. The relative contribution of all psychotropic drugs to improvement of BPD symptomatology was assessed by means of a stepwise logistic regression. Results None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio [OR] 43.2, p ≤ 0.0001). Patients treated with naltrexone (N = 55, 34%) recovered significantly more often. Higher doses of naltrexone were more effective (OR 791.8, p ≤ 0.0001) than lower doses (OR 26.6, p ≤ 0.0001); however, even low‐dose treatment was better than any other pharmacological treatment. Conclusions Naltrexone was associated with improvement in BPD in a dose‐dependent manner. The present study provides additional evidence that dysregulation of the endogenous opioid system is implicated in the pathophysiology of BPD symptoms."],["dc.description.sponsorship","Georg‐August‐Universität Göttingen, Open Access Publication Funds of the Göttingen University http://dx.doi.org/10.13039/501100003385"],["dc.identifier.doi","10.1002/hup.2800"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85064"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1099-1077"],["dc.relation.issn","0885-6222"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","German Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","7"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Jacobs, Stefan"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Schneider, Udo"],["dc.contributor.author","Cimander, Konrad"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2019-07-10T08:13:27Z"],["dc.date.available","2019-07-10T08:13:27Z"],["dc.date.issued","2009"],["dc.description.abstract","Objective: Previous reports on heroin and cocaine addicts showed drug-related and gender differences in psychiatric comorbidity, which has relevant consequences for treatment. However, studies vary substantially with respect to methods and timeframes. Studies on German patient groups are scarce. Methods: Data on psychiatric and somatic comorbidity, substance addiction history, present intake patterns and sociodemography were obtained from 43 female (n=11) and male (n=32) heroin and cocaine addicts in acute inpatient detoxification treatment or specified long-term treatment. A European Addiction-Severity-Index (EuropASI) based centre questionnaire and the Mini-DIPS were applied. Results: Treatment groups did not differ in psychiatric comorbidity. Female subjects, however, had a significantly higher prevalence of psychiatric comorbid diagnoses (p<.05), mostly anxiety and affective disorders which significantly correlated with low occupational status (p<.05).Patients in long-term treatment abused more other substances and had an earlier onset of regular substance abuse (in particular alcohol and cannabis) (p<.05). Conclusion: Heroin and cocaine addicted females are more likely than males to have affective and anxiety disorders. Long-term treatment attenders appear to be more severely addicted (earlier onset and additional abuse) than acute treatment patients but do not differ in comorbidity. However, no axis-II diagnoses were recorded and the sample-size was small. Results should be regarded as preliminary (German J Psychiatry 2009; 12: 1-7)."],["dc.identifier.fs","541930"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5950"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61249"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1455-1033"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Psychiatric Comorbidity and Gender Effects in Heroin and Cocaine-Addicted Patients in Specified Long-Term Treatment and Acute Inpatient Detoxification Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2722"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","2727"],["dc.bibliographiccitation.volume","260"],["dc.contributor.author","Kaerst, Lisa"],["dc.contributor.author","Kuhlmann, Andre"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Lange, Peter"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:18:09Z"],["dc.date.available","2018-11-07T09:18:09Z"],["dc.date.issued","2013"],["dc.description.abstract","Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer's disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and A42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. A42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls."],["dc.identifier.doi","10.1007/s00415-013-7047-3"],["dc.identifier.isi","000326400800003"],["dc.identifier.pmid","23877436"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10310"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28341"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1432-1459"],["dc.relation.issn","0340-5354"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","63"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Alzheimer s Disease"],["dc.bibliographiccitation.lastpage","73"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Kaerst, Lisa"],["dc.contributor.author","Kuhlmann, Andre"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Lange, Peter"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:47:20Z"],["dc.date.available","2018-11-07T09:47:20Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Dementia with Lewy bodies (DLB) is difficult to differentiate from other neuro-degenerative diseases. Patients are often mistaken to suffer from Parkinson's disease (PD) or Alzheimer's disease (AD) because of the overlapping clinical appearances concerning cognition and movement. Objective: We investigated the possibility for a valid differential diagnosis using cerebrospinal fluid (CSF) biomarkers. Methods: In the context of a large retrospective study, we analyzed data of patients suffering from degenerative, ischemic, or inflammatory CNS (central nervous system) diseases and identified those with DLB (n = 34), PD (n = 37), and AD (n = 47) for further analyses. Results: We detected abnormalities in the CSF profiles of those patients with DLB while using a combination of decreased amyloid-alpha(A beta) 42 and increased tau levels. By stratification of data by disease severity, we observed a high sensitivity of this combination especially in the subgroup of patients with advanced stages, while the sensitivity in early forms was lower. In addition, with clinical deterioration, the abnormalities in the CSF profile became more pronounced. Conclusion: We conclude that DLB can be distinguished from PD, in spite of both being synucleinopathies, by CSF profiles using neurodegenerative marker analysis. The pathophysiology of increased tau and decreased A beta levels in those conditions has to be elucidated further, since both proteins are known to be involved in the pathogenesis of AD, but no clear explanation has been postulated for DLB yet."],["dc.identifier.doi","10.3233/JAD-130995"],["dc.identifier.isi","000326380300005"],["dc.identifier.pmid","23948928"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35085"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.relation.issn","1875-8908"],["dc.relation.issn","1387-2877"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Using Cerebrospinal Fluid Marker Profiles in Clinical Diagnosis of Dementia with Lewy Bodies, Parkinson's Disease, and Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1"],["dc.bibliographiccitation.journal","Substance Abuse Treatment Prevention and Policy"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Heitmann, Soren"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Engel, Kirsten-Rita"],["dc.contributor.author","Huether, Gerald"],["dc.date.accessioned","2018-11-07T09:29:13Z"],["dc.date.available","2018-11-07T09:29:13Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Insecure early attachment experiences have been reported to play an important role in the manifestation in alcoholism. The purpose of this study was to investigate the relationship of attachment styles with anxiety, anxiety coping and dysfunctional personality styles, as well as with the prevalence of personality disorders, and adverse life-events in adolescence. Methods: 59 inpatient alcohol addicted male (n=43) and female (n=16) patients were characterized by an attachment style scale (Relationships-style-questionnaire-RSQ) and completed a questionnaire battery comprising the State-Trait-Anxiety-Inventory (STAI), the Anxiety-Coping-Inventory (ABI), Temperament-and-character-inventory (TCI), Personality-system-interaction-inventory (PSI), and gave information on sociodemography, alcohol history, and adolescent adverse events. A structured interview (SKID-II) was performed to diagnose personality disorders. Results: Only 33% of subjects had a secure attachment style. Insecure attachment was associated with significantly higher trait-anxiety, higher cognitive avoidance to control anxiety, and higher values on most personality style dimensions directed to the pathological pole. Conclusions: Despite the limitation due to a small sample size, the results of this study show that the consideration of attachment styles is of significance in the diagnosis and therapy of alcohol addiction. Attachment may characterize different styles to control emotional aspects, anxiety cues and interpersonal relationships in individuals suffering from alcohol addiction."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2013"],["dc.identifier.doi","10.1186/1747-597X-8-1"],["dc.identifier.isi","000317649000001"],["dc.identifier.pmid","23302491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8903"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30968"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1747-597X"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","703"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","716"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2018-11-07T08:29:27Z"],["dc.date.available","2018-11-07T08:29:27Z"],["dc.date.issued","2009"],["dc.description.abstract","Neuroimaging studies have gained increasing importance in validating neurobiological network hypotheses for anxiety disorders. Functional imaging procedures and radioligand binding studies in healthy subjects and in patients with anxiety disorders provide growing evidence of the existence of a complex anxiety network, including limbic, brainstem, temporal, and prefrontal cortical regions. Obviously, \"normal anxiety\" does not equal \"pathological anxiety\" although many phenomena are evident in healthy subjects, however to a lower extent. Differential effects of distinct brain regions and lateralization phenomena in different anxiety disorders are mentioned. An overview of neuroimaging investigations in anxiety disorders is given after a brief summary of results from healthy volunteers. Concluding implications for future research are made by the authors."],["dc.identifier.doi","10.1007/s00702-008-0077-9"],["dc.identifier.isi","000266926100010"],["dc.identifier.pmid","18568288"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3558"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16654"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Neuroimaging in anxiety disorders"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Psychiatry"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Timäus, Charles"],["dc.contributor.author","Meiser, Miriam"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Engel, Kirsten R."],["dc.contributor.author","Paschke, Anne M."],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2020-12-10T18:38:54Z"],["dc.date.available","2020-12-10T18:38:54Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s12888-019-2377-z"],["dc.identifier.eissn","1471-244X"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16935"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77475"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]